Transcriptome Analysis of the Peripheral Blood in CIDP

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT02404298
• Date of registration: 06/02/2015
• Prospective Registration: No
• Primary sponsor: Assistance Publique - Hôpitaux de Paris
• Public title: Transcriptome Analysis of the Peripheral Blood in CIDP PHARMACOPID
• Scientific title: Identification of the Mechanisms of Action of Intravenous Immunoglobulins in CIDP by Analysis of the Genetic Expression Profile in Blood Mononuclear Cells
• Date of first enrolment: February 2015
• Target sample size: 50
• Recruitment status: Unknown status
• URL: https://clinicaltrials.gov/show/NCT02404298
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: N/A

Countries of recruitment

France

Contacts

• Name: Karine Viala, MD
• Affiliation: Assistance Publique - Hôpitaux de Paris

Key inclusion & exclusion criteria

Inclusion criteria :

- Age = 18 years old

- Obtained informed consent

- Patient having a definite or probable CIDP according to EFNS/PNS criteria or atypical
CIDP corresponding to patients having the EFNS/PNS clinical criteria and at least two
EFNS/PNS supportive criteria

- Or

- Patient having a muscular autoimmune disease, or a Clarkson syndrome or other
autoimmune disease

- Currently treated by IVIG

Exclusion criteria :

- pregnancy

- breastfeeding



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Clarkson Syndrome

Muscular Autoimmune Disorders

Autoimmune Diseases

Intervention(s)

Drug: IVIg

Primary Outcome(s)

Gene expression profile [Time Frame: 3 weeks]

Secondary Outcome(s)

IgG [Time Frame: 3 weeks]

Gene expression profile in each lymphocytary sub-group [Time Frame: 3 weeks]

Secondary ID(s)

P111122

Source(s) of Monetary Support

Please refer to primary and secondary sponsors